Navamedic — M&A Activity 2023

Apr 22, 2023

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Oslo, 22 April 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and

provider of high-quality products to hospitals and pharmacies, has today amended

its cash offer to acquire all shares in Sensidose AB (the "Offer") and at the

same time agreed to purchase 6,837,016 shares in Sensidose AB representing 57.2%

of the outstanding shares. The Sensidose shares are currently listed on

Spotlight Stock Market in Sweden.

Navamedic ASA ("Navamedic") has today amended its Offer to SEK 8.00 per share in

Sensidose AB ("Sensidose") representing a total purchase price of approximately

SEK 96 million for all the outstanding shares in Sensidose. The Offer has at the

same time been declared unconditional and the acceptance period for the Offer

has been extended with 2 weeks (expiring on 8 May 2023).

Navamedic has also entered into unconditional agreements to acquire 6,837,016

shares in Sensidose (including shares tendered in the Offer), representing 57.2%

of the outstanding shares, at a purchase price of SEK 8.00 per share.

For further information about the Offer, please see the attached press release

regarding the amended Offer.

Carnegie Investment Bank is acting as financial advisor to Navamedic. Roschier

Advokatbyrå AB and Advokatfirmaet Thommessen AS are acting as legal advisors to

Navamedic. First House AS is acting as communications and IR advisor to

Navamedic.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality

products, delivered to hospitals and through pharmacies, meeting the specific

needs of patients and consumers by leveraging its highly scalable market access

platform, leading category competence and local knowledge. Navamedic is present

in all the Nordic countries, the Baltics and Benelux, with sales representation

in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on

the Oslo Stock Exchange (ticker: NAVA). For more information, please

visitwww.navamedic.com

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation and is subject to the disclosure requirements pursuant

to Section 5-12 the Norwegian Securities Trading Act. The information was

submitted for publication, through Newsweb by Lars Hjarrand at 13.10 hrs CEST on

22 April 2023.